21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other...
21:41 , Jul 24, 2017 |  BC Extra  |  Preclinical News

Group identifies ZFN326 gene as possible TNBC target

In a paper published in Cancer Research , researchers identified four tumor suppressor genes in triple-negative breast cancer, including one whose expression may be associated with patient survival. The paper's authors included researchers from Houston...
07:00 , Jun 10, 2013 |  BC Week In Review  |  Company News

Allon, Paladin neurology news

Paladin proposed to purchase all issued and outstanding Allon shares for C$1 total, plus C$900,000 ($867,807) in cash. Allon believes that its creditors "will derive a greater benefit as a result" of the proposed acquisition...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Davunetide: Phase II/III data

Allon said it will not allocate any additional capital to R&D for davunetide after top-line data from a double-blind, international Phase II/III trial in 313 patients with PSP showed that twice-daily 30 mg davunetide administered...
02:15 , Dec 19, 2012 |  BC Extra  |  Clinical News

Allon plummets on davunetide update

Allon Therapeutics Inc. (TSX:NPC) fell C$0.41 (94%) to C$0.03 on Tuesday after the company said it will not allocate any additional capital to R&D for davunetide and will take immediate action to reduce its operating...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

Davunetide: Phase II/III ongoing

Allon said an independent DSMB recommended for the fourth time the continuation of an international, double-blind, placebo-controlled Phase II/III trial evaluating 30 mg davunetide given twice daily for 52 weeks in 300 patients. The company...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

Davunetide: Phase II/III ongoing

Allon said an independent DSMB recommended continuation of an international, double-blind, placebo-controlled, Phase II/III trial evaluating 30 mg davunetide given twice daily for 52 weeks in about 300 patients. The company has an SPA from...
07:00 , Oct 31, 2011 |  BC Week In Review  |  Clinical News

Davunetide: Completed Phase II/III enrollment

Allon completed enrollment of 300 patients in a double-blind, placebo-controlled, international pivotal Phase II/III trial evaluating 30 mg davunetide twice daily for 52 weeks. The company has an SPA from FDA for the trial. Davunetide...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

Allon preclinical data

In a mouse model of PD, intranasal davunetide for 2 months significantly improved motor performance and coordination by 38% vs. vehicle-treated controls (p<0.01). Data were published in Molecular and Cellular Neuroscience. Davunetide is in Phase...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

Davunetide: Phase II/III started

Allon began a double-blind, placebo-controlled, international, pivotal Phase II/III trial to evaluate 30 mg davunetide twice daily for 52 weeks in about 300 patients. The company has an SPA from FDA for the trial. Davunetide...